ASML has bounced hard from its early-June lows, adding 5.2% on the week and 19.6% over the past month to close at €1,461.80 — and that recovery sharpens rather than resolves the tension that defined last week's note: a stock running ahead of consensus, now running even further ahead.
The most striking development is purely arithmetic. A trailing P/E of 41.2x and a price-to-book of 21.7x were already elevated; both have expanded materially over the past 30 days, with the P/E up nearly 6.8 turns and the P/B up 3.5 turns. EV/EBITDA has risen to 31.9x. These aren't small moves — they reflect a market that has repriced ASML upward faster than earnings estimates have followed. The EPS momentum score ranks in the 44th percentile on a 30-day basis and the 50th percentile over 90 days: squarely in line with the broad market, not leading it. The business quality case — F-Score of 8, strong return on assets, healthy free cash flow margins — remains intact and scores near the 95th percentile in ORTEX factor rankings. But quality alone is doing more and more of the work to justify the multiple.
The lending market tells a clean, unambiguous story: there is essentially no short pressure here. Borrow availability is at its maximum measurable level, with over 175 million shares available to lend against negligible demand. Cost to borrow has fallen roughly 27% on the week to 0.69% — already low, now lower. The ORTEX short score of 25.3 ranks in the 96th percentile of the universe for short-side conviction, meaning shorts are effectively absent. That dynamic cuts both ways: it confirms there is no crowded-short story threatening a squeeze, but it also means any further price appreciation is entirely driven by long-side demand, with no forced-cover fuel underneath it.
Peer performance this week adds context. Close correlated peers AMAT and LRCX both outpaced ASML on the day — AMAT gaining 7.0% and LRCX 5.5% versus ASML's 4.9% — while KLAC added 5.4%. On the week, AMAT was the standout at 7.7% versus ASML's 5.2%. The sector move is broad and macro-driven rather than ASML-specific, which matters: when the whole group rallies together, ASML's premium valuation is less of a differentiator in either direction. Amsterdam-listed peers ASM and BESI lagged, up 2.4% and 2.9% on the day respectively.
Institutional ownership is steady. BlackRock holds 7.2% and trimmed fractionally last month; Fidelity (FMR) added around 827,000 shares in April, the largest single move among top holders. The insider picture — where the most recent disclosed activity was February's routine award-and-sell cluster by the CEO, CFO, and COO at around €1,207 — remains quiet and consistent with standard equity compensation practices. No directional read should be taken from it.
The note published two days ago flagged that ASML was trading roughly 13% above the Street's mean target. At €1,461.80, that gap has compressed only marginally from the prior close of €1,612.76 (USD-denominated in the earlier note, reflecting the ADR listing). Analyst data on file is stale and should not be quoted as current. What is current is the July 15 earnings date — the next hard catalyst — and the question it poses: whether Q2 order intake and EUV shipment guidance can catch up with a multiple that has re-rated sharply ahead of the print.
See the live data behind this article on ORTEX.
Open ASML on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
